



1600 20th Street, NW • Washington, D.C. 20009 • 202/588-1000 • www.citizen.org

POST-TRIPS Examples of Compulsory Licensing for Pharmaceuticals Worldwide

Year	Country	Medications	Type	Results
2002	Zimbabwe	Any drug used for the treatment of HIV/AIDS.	Emergency	The average price of ARVs dropped from \$30 to \$50 per month to just over \$15 a month, cutting the price by at least 50%.
2003	Malaysia	3 ARVs: ddl; AZT; and 3TC + AZT (Combivir).	Government use	Average cost reduction of about 81% per patient per month; number of patients treated by public services increased from 1,500 to 4,000.
2004	Mozambique	3 ARVs: 3TC; d4T; and NVP.	Extreme emergency	
2004	Zambia	ARV: 3TC; d4T; and AZT.	Extreme emergency	
2004, 2007, 2012	Indonesia	2004—2 ARVs: NVP; 3TC 2007—3 ARVs: NVP; 3TC; and EVF 2012—Seven ARVs (EVF; ABC; ddl; LPV/RTV; TDF; TDF + FTC; and TDF + FTC + EFV) and a hepatitis B medication.	Government use	About 2000 patients received free access to ARVs after the first two licenses.
2005	Eritrea	ARVs	Emergency; Government use	
2005	Ghana	ARVs	Emergency; Government use	Annual price for ARVs dropped by 50%.
2005, 2006, 2007	Italy	<p>2005—The active ingredient is an antibiotic combination: imipenem + Cilastatin.</p> <p>2006—The active ingredient for a medication used to treat migraines: sumatriptan succinate.</p> <p>2007—The active ingredient for a medication used to treat prostate cancer, prostrate hypertrophy, and male baldness: finasteride.</p>	Anti-competitive practices	

2006, 2007, 2008	Thailand	2006 —1 ARV: EFV. 2007 —2 ARVs (LPV/RTV) and a drug used to treat cardiovascular diseases (clopidogrel) 2008 —Treatments for cancer: docetaxel; erlotinib; letrozol; imatinib (ultimately the imatinib the compulsory license was not needed due to the successful negotiations with patent holders).	Government use	The price of EFV was reduced by 85.71%; LPV/RTV by 75%; clopidogrel by 91%; docetaxel by 95.83%; letrozol by 98.6%. After the CL, Abbott cut the price of LPV/RTV by more than 55% for over 40 countries, and Merck cut the price of EFV by 62% worldwide. Patients accessing LPV/RTV tripled. By 2010, the number of patients receiving EFV increased from 4,539 to 29,360 in Thailand.
2007	Brazil	EFV	Government use	CL produced immediate savings of US\$31.5 million.
2007	Canada	AZT + 3TC + NVP	Paragraph 6 allowance – Patent Act of Canada § 21.04	Canada amended its domestic patent laws in order to take advantage of the Doha Declaration's Paragraph 6 waiver of Article 31(f) of the TRIPS agreement. The Canadian generic manufacturer, Apotex, then exported the AZT, 3TC, & NVP combination therapy to Rwanda, therein becoming the first nation to take advantage of the Doha Declaration's paragraph 6 flexibility.
2007	Rwanda	AZT + 3TC + NVP	Public interest	Rwanda imported 15.6 million tablets of this combination at a cost of US \$0.405 per tablet.
2009, 2010, 2012	Ecuador	2010 —ARV: RTV 2012 —ARV: ABC + 3TC 2014 —Treatments for cancer (sunitinib); rheumatoid arthritis (certolizumab); arthritis (etoricoxib); and immunological reception to kidney transplants (Mycophenolate sodium).	Public interest	30% reduced price offer for ritonavir.
2012	India	Medication for the treatment of kidney and liver cancer: sorafenib tosylate.	Public interest / failure to commercialize	It is estimated that the price of the drugs will be reduced by 97%, from US\$5,500 to US\$ 175 per patient per month.

Legend: 3TC= lamivudine / ABC= abacavir / AZT= zidovudine / d4t= stavudine / ddl= didanosine / EVF= efavirenz / FTC= emtricitabine / LPV= lopinavir / NVP= nevirapine / RTV= ritonavir / TDF= tenofovir